Share
Save
Non-Alcoholic Steatohepatitis (NASH) clinical trial
Join a clinical trial exploring a potential new treatment for Non-Alcoholic Steatohepatitis (NASH) and help advance liver disease research.
Study details:
This clinical research study evaluates the safety and effectiveness of an investigational medication for Non-Alcoholic Steatohepatitis (NASH), a progressive liver condition that can lead to serious complications. The study aims to explore treatments that may improve liver health and quality of life. Participants will take the investigational medication or a placebo for 28 days while continuing their usual medications. Trial-related care, including exams, imaging, and lab tests, will be provided at no cost. Eligible participants may also receive compensation for time and travel. This Phase 1 study will look at how safe and well-tolerated INI-822 is, as well as how the body absorbs and responds to it. The study will involve people who have had Non-Alcoholic Steatohepatitis (NASH) or are believed to have it. Trial related procedures and the study medication will be provided at no cost. Participants who qualify may be compensated for time and travel.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
Things to know
Study dates
Study start: 2025-01-01
Primary completion: 2025-11-15
Study completion finish: 2025-12-15
Study type
TREATMENT
Phase
PHASE1
Trial ID
INI-822-001
Intervention or treatment
DRUG: INI-822 (A)
OTHER: Placebo (B)
Conditions
- • Non-alcoholic Steatohepatitis
Find a site
Closest Location:
The Alfred Hospital
Research sites nearby
Select from list below to view details:
The Alfred Hospital
Melbourne, Victoria, Australia
St. Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
The Queen Elizabeth Hospital
Woodville, South Australia, Australia
CMAX Clinical Research
Adelaide, South Australia, Australia
Frequently Asked Questions
Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol
No questions submitted. Be the first to ask a question!